Prevention of recurrent aphthous stomatitis with colchicine: An open trial

Katz, Joseph; Langevitz, Pnina; Shemer, Joshua; Barak, Shlomo; Livneh, Avi

doi:10.1016/s0190-9622(94)70211-x

Cited by 70 publications

(42 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Colchicine was initially reported to have a favorable outcome in small groups of patients with RAS (Gatot and Tovi, 1984;Ruah et al, 1988), and, in a more recent open study of 20 patients, colchicine (1.5 mg/day for 2 months) produced a significant reduction in pain scores and frequency of self-reported ulcers (Katz et al, 1994). Unfortunately, not all patients benefit from colchicine therapy, and at least 20% can have painful gastrointestinal symptoms or diarrhea (Katz et al, 1994), and it can produce infertility in young males. Combined colchicine and thalidomide therapy may occasionally benefit recalcitrant RAS (Genvo et al, 1984).…”

Section: Management (A) Diagnosismentioning

confidence: 98%

Recurrent Aphthous Stomatitis

Porter

Scully

Pedersen

1998

Critical Reviews in Oral Biology & Medicine

249

143

View full text Add to dashboard Cite

show abstract

Section: Management (A) Diagnosismentioning

confidence: 98%

Recurrent Aphthous Stomatitis

Porter

Scully

Pedersen

1998

Critical Reviews in Oral Biology & Medicine

249

143

View full text Add to dashboard Cite

show abstract

“…This fact can be best revealed by conducting double blind clinical trials. 9,14 Our results showed that in Middle Eastern populations such as Iran, colchicine seems to have a higher efficacy and can thus be used in low doses. In 1994 in an open trial, Katz and colleagues studied the effects of colchicine on prevention of RAS in 20 patients in a four months follow-up study.…”

Section: Discussionmentioning

confidence: 65%

“…In 1994 in an open trial, Katz and colleagues studied the effects of colchicine on prevention of RAS in 20 patients in a four months follow-up study. 9 The patients did not take any medication in the first two months of the study, but were given a daily dose of 1.5 mg colchicine over the next two months. There was a 71% and 77% reduction in the number of ulcers and intensity of pain, respectively, in comparison with the first two months (p< 0.001).…”

Section: Discussionmentioning

confidence: 99%

“…[1][2][3][4]6,7 Positive effects of corticosteroids in reducing the pain and burning sensation and the number of ulcers, as well as ability of colchicine to minimize the duration and number of aphthous ulcers have been shown in several studies. [8][9][10][11] Proposed mechanisms of action of prednisolone include suppression of granulocyte migration to the site of tissue injury, phagocytosis, prostaglandin and leukotriene synthesis and the cellular immunity. 4,12,13 The antiinflammatory action of colchicine is caused by the binding to microtubular protein and suppressing the migration and phagocytosis of leukocytes, and the generation of leukotriene B4 and lactic acid products.…”

mentioning

confidence: 99%

See 1 more Smart Citation

Comparison of colchicine versus prednisolone in recurrent aphthous stomatitis: A double-blind randomized clinical trial

Pakfetrat¹,

Mansourian²,

Momen-Heravi³

et al. 2010

CIM

View full text Add to dashboard Cite

Clin Invest Med 2010; 33 (3): E189-E195. AbstractPurpose: Recurrent aphthous stomatitis (RAS) is one of the most common ulcers of the oral cavity with a reported prevalence of 5-50%. There is still no definitive treatment for RAS; however, immunosuppressive and immunomodulant agents have been proposed. In this study, we compared the therapeutic effects of 5 mg/d prednisolone with 0.5 mg/ d colchicine in the treatment of RAS. Methods: In a double-blind randomized clinical trial, 34 patients with RAS were randomly divided into two groups for treatment with prednisolone or colchicine. All patients took the medication for three months and were assessed at two weeks intervals. The groups were compared for size and number of lesions, severity of pain and burning sensation, duration of pain-free episodes and any side effects of the prescribed medicines. Both colchicine and prednisolone treatments significantly reduced RAS (p<0.001). No significant differences in size and number of lesions, recurrence and severity of pain and duration of pain-free period were seen between the two treatment groups. Colchicine (52.9%) had significantly more side effects than prednisolone (11.8%). Conclusion: Low dose prednisolone and colchicine were both effective in treating RAS. Given that the two therapies had similar efficacy, yet colchicine was associated with more side effects, , 5mg/d of prednisolone seems to be a better alternative in reducing the signs and symptoms of the disease.Recurrent aphthous stomatitis (RAS) is one of the most common ulcers of the oral cavity with a reported prevalence of 5-50%. 1-3 Several etiologies have been proposed for RAS but the exact cause still remains unknown. According to severity and location of the lesions, different types of topical or systemic treatments have been used, but none of them have shown ORIGINAL RESEARCH

show abstract

“…13 However, it has several serious adverse effects, including a well-documented teratogenic potential and irreversible polyneuropathy. Colchicine has also been effective in some patients, [14][15][16] and is thought to work through its inhibitory effect on neutrophil function, chemotaxis, and adhesion molecule expression. 17 Unfortunately, only a proportion of patients benefit from it, and its use is complicated by potentially serious adverse effects, including gastrointestinal upset, renal and hepatic damage, male infertility, and blood dyscrasias.…”

mentioning

confidence: 99%